Nephrology News

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Request Information

Invalid Input
Invalid Input
Invalid Input
Invalid Input